- 同
- Interleukin-3 receptor, α-chain
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/08/14 08:59:14」(JST)
[Wiki en表示]
interleukin 3 receptor, alpha |
Identifiers |
Symbol |
IL3RA |
Alt. symbols |
CD123 |
HUGO |
6012 |
OMIM |
308385 |
Other data |
Locus |
Chr. X p22.3 |
interleukin 3 receptor, Y-Chromosomal |
Identifiers |
Symbol |
IL3RA |
Alt. symbols |
IL3RY, IL3RAY |
Entrez |
3563 |
HUGO |
6012 |
OMIM |
430000 |
Other data |
Locus |
Chr. Y p11.3 |
The interleukin-3 receptor (also known as CD123 antigen) is a molecule found on cells which helps transmit the signal of interleukin-3, a soluble cytokine important in the immune system.
The gene coding for the receptor is located in the pseudoautosomal region of the X and Y chromosomes.
The receptor belongs to the type I cytokine receptor family and is a heterodimer with a unique alpha chain paired with the common beta (beta c or CD131) subunit.
The gene for the alpha subunit is 40 kilobases long and has 12 exons.
Contents
- 1 Cell types and function
- 2 Possible drug target
- 3 References
- 4 External links
Cell types and function
The receptor, found on pluripotent progenitor cells, induces tyrosine phosphorylation within the cell and promotes proliferation and differentiation within the hematopoietic cell lines. It can be found on basophils and pDCs as well as some cDCs among peripheral blood mononuclear cells.
CD123 is expressed across acute myeloid leukemia (AML) subtypes, including leukemic stem cells.[1]
Possible drug target
An experimental antibody-drug conjugate SGN-CD123A targets CD123 as a possible treatment for AML.[1]
References
- ^ a b Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia Sept 2016
External links
- Interleukin-3 Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
Cytokine receptors
|
Chemokine receptor
(GPCRs) |
CC |
- CCR1 / CCRL1
- CCR2
- CCRL2
- CCR3
- CCR4
- CCR5
- CCR6
- CCR7
- CCR8
- CCR9
- CCR10
|
CXC |
- IL-8
- CXCR3
- CXCR4
- CXCR5
- CXCR6
- CXCR7
|
Other |
|
|
TNF receptor |
1-10 |
- TNFR1 (TNFRSF1A)
- TNFR2 (TNFRSF1B)
- LTBR (TNFRSF3)
- CD134 (TNFRSF4)
- CD40 (TNFRSF5)
- Fas receptor (TNFRSF6)
- DcR3 (TNFRSF6B)
- CD27 (TNFRSF7)
- CD30 (TNFRSF8)
- CD137 (TNFRSF9)
|
11-20 |
- DR4 (TNFRSF10A)
- DR5 (TNFRSF10B)
- DcR1 (TNFRSF10C)
- DcR2 (TNFRSF10D)
- RANK (TNFRSF11A)
- Osteoprotegerin (TNFRSF11B)
- TweakR (TNFRSF12A)
- TACI (TNFRSF13B)
- BAFFR (TNFRSF13C)
- HVEM (TNFRSF14)
- NGFR (TNFRSF16)
- BCMA (TNFRSF17)
- GITR (TNFRSF18)
- TAJ/TROY (TNFRSF19)
|
21-27 |
- DR6 (TNFRSF21)
- DR3 (TNFRSF25)
- EDA2R (TNFRSF27)
|
|
JAK-STAT |
Type I |
γ-chain |
- Interleukin receptors
- IL2R / IL2RA/IL2RB / IL15R
- IL4R / IL13R / IL13RA1 / IL13RA2
- IL7R / IL7RA
- IL9R
- IL21R
|
β-chain |
- Interleukin receptors
- IL3R / IL3RA
- IL5R / IL5RA
- GM-CSF
|
gp130 |
- Interleukin receptors
- IL6RA
- 11/IL11RA
- 27/IL27RA
- OSMR
- LIFR
- CNTFR
|
IL12RB1 |
- Interleukin receptors
- IL12R/IL12RB1/IL12RB2
- IL23R23
|
Other |
- hormone receptor: GH
- prolactin
|
|
Type II |
- Interleukin receptors
- IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
- IL20R / IL20RA / IL20RB
- IL28R
- Interferon receptors
- -α/β / IFNAR1/IFNAR2
- -γ/IFNGR1 / IFNGR2
|
|
Ig superfamily |
- CSF1
- KIT
- IL1
- IL18R / IL18R1
|
IL 17 family |
- IL17
- IL17RA
- IL17RB
- IL17RC
- IL17RD
- IL17RE
|
S/T |
|
Interleukin receptor modulators
|
IL-1 |
- Agonists: Interleukin 1 (α, β)
- Mobenakin
- Pifonakin
- Antagonists: AF-12198
- Anakinra
- IL-1RA
- Isunakinra
- Antibodies: Canakinumab
- Gevokizumab
- Lutikizumab
- Decoy receptors: Rilonacept (IL-1 Trap)
|
IL-2 |
- Agonists: Adargileukin alfa
- Aldesleukin
- Celmoleukin
- Denileukin diftitox
- Interleukin 2
- Pegaldesleukin
- Teceleukin
- Tucotuzumab celmoleukin
- Antibodies: Basiliximab
- Daclizumab (dacliximab)
- Inolimomab
|
IL-3 |
- Agonists: Daniplestim
- Interleukin 3
- Leridistim
- Milodistim
- Muplestim
- Promegapoietin
|
IL-4 |
- Agonists: Binetrakin
- Interleukin 4
- Interleukin 13
- Antibodies: Dupilumab
- Pascolizumab
|
IL-5 |
- Antibodies: Benralizumab
- Mepolizumab
- Reslizumab
- Antisense oligonucleotides: TPI ASM8
|
IL-6 |
- Agonists: Atexakin alfa
- Interleukin 6
- Antibodies: ARGX-109
- Clazakizumab
- Elsilimomab
- mAb 1339
- Olokizumab
- Sarilumab
- Siltuximab
- Sirukumab
- Tocilizumab
|
IL-7 |
|
IL-8 |
- See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
|
IL-9 |
|
IL-10 |
- Agonists: Ilodecakin
- Interleukin 10 (CSIF)
|
IL-11 |
- Agonists: Interleukin 11 (AGIF)
- Oprelvekin
|
IL-12 |
- Agonists: Edodekin alfa
- Interleukin 12
- Antibodies: Briakinumab
- Ustekinumab
|
IL-13 |
- Agonists: Binetrakin
- Cintredekin besudotox
- Interleukin 4
- Interleukin 13
- Antibodies: Anrukinzumab
- Lebrikizumab
- Tralokinumab
|
IL-15 |
- Agonists: ALT-803
- Interleukin 15
|
IL-17 |
- Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)
- Antibodies: Brodalumab
- Ixekizumab
- Perakizumab
- Remtolumab
- Secukinumab
- Vunakizumab
|
IL-18 |
- Agonists: Iboctadekin
- Interleukin 18
- Interleukin 37
- Tadekinig
|
IL-20 |
- Agonists: Interleukin 19
- Interleukin 20
- Interleukin 24
- Antibodies: Fletikumab (against IL-20)
|
IL-21 |
- Agonists: Denenicokin
- Interleukin 21
- Antibodies: NNC0114-0005
- NNC0114-0006
|
IL-22 |
- Antibodies: Fezakinumab (against IL-22)
|
IL-23 |
- Agonists: Interleukin 23 (SGRF)
- Antibodies: Brazikumab
- Briakinumab
- Guselkumab
- Tildrakizumab
- Ustekinumab
|
IL-27 |
- Agonists: Interleukin 27 (interleukin 30)
|
IL-28 |
- Agonists: Interferon λ4 (IFN-λ4)
- Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
- Interleukin-29 (IFN-λ1)
|
IL-31 |
|
IL1RL1 |
|
IL1RL2 |
- Agonists: Interleukin 36 (α, β, γ)
- Interleukin 38
|
Others |
JAK
|
|
Others
|
- Interleukin 14 (taxilin alpha, HMW-BCGF)
- Interleukin 16 (signals through CD4)
- Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer)
- Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer)
- Interleukin 32
- Interleukin 34 (signals through M-CSFR/CSF1R)
- Interleukin 35
|
|
- See also: Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Cytokine receptor modulators
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Conjunctival extranodal natural killer/t-cell lymphoma, nasal type.
- Kiratli H1, Uzun S, Yeşilirmak A, Ayhan AS, Soylemezoğlu F.
- Cornea.Cornea.2015 Jun;34(6):710-2. doi: 10.1097/ICO.0000000000000420.
- PURPOSE: To report a rare case of a patient with isolated primary conjunctival extranodal natural killer/T-cell lymphoma, nasal type (ENKTCL) without nasal involvement.METHODS: The clinical course, magnetic resonance imaging, positron emission tomographic and immunohistopathological features of the
- PMID 25811726
- Blastic plasmacytoid dendritic cell neoplasm: skin and bone marrow infiltration of three cases and the review of the literature.
- Atalay F1, Demirci GT2, Bayramgürler D3, Ateşoğlu EB4, Yıldız S5.
- Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion.Indian J Hematol Blood Transfus.2015 Jun;31(2):302-6. doi: 10.1007/s12288-014-0464-3. Epub 2014 Oct 14.
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a distinct and rare neoplastic entity and was classified as a subgroup of acute myeloblastic leukemia by the WHO in 2008. The median survival of patients was 15.2 months in a large case series. Allogeneic or autologous bone marrow transplantat
- PMID 25825579
- A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates.
- Chichili GR1, Huang L1, Li H1, Burke S1, He L1, Tang Q1, Jin L1, Gorlatov S1, Ciccarone V1, Chen F1, Koenig S1, Shannon M1, Alderson R1, Moore PA1, Johnson S1, Bonvini E2.
- Science translational medicine.Sci Transl Med.2015 May 27;7(289):289ra82. doi: 10.1126/scitranslmed.aaa5693.
- Current therapies for acute myeloid leukemia (AML) are largely ineffective, and AML patients may benefit from targeted immunotherapy approaches. MGD006 is a bispecific CD3xCD123 dual-affinity re-targeting (DART) molecule that binds T lymphocytes and cells expressing CD123, an antigen up-regulated in
- PMID 26019218
Japanese Journal
- Th1/Th2 関連疾患における末梢血樹状細胞サブセットの解析
- 林 ゆめ子
- Dokkyo journal of medical sciences 40(1), T13-T22, 2013-03-25
- … 究では,Th1疾患であるサルコイドーシス( サ症)( n=30)とTh2疾患であるアトピー性疾患( n=23)における末梢血DC サブセットを,健常人 (n=23)と比較して検討した.フローサイトメトリーを用いて末梢血中のmDC(CD11c+),pDC( CD123+),mDC1( CD1a+),mDC2( CD141+)のサブセット解析を行った.サ症群では総DC, mDC の数が有意に低下していた.mDC/pDC 比は3 群間で差がなかった.CD1a+mDC は,サ症群では対照群と差がなかったが,アトピー群ではCD1a+mDC …
- NAID 110009561263
- Leukemic Manifestation of Blastic Plasmacytoid Dendritic Cell Neoplasm Lacking Skin Lesion : A Borderline Case between Acute Monocytic Leukemia
- TAKIUCHI Yoko,MARUOKA Hayato,AOKI Kazunari,KATO Aiko,ONO Yuichiro,NAGANO Seiji,ARIMA Hiroshi,INOUE Daichi,MORI Minako,TABATA Sumie,YANAGITA Soshi,MATSUSHITA Akiko,NISHIO Mari,IMAI Yukihiro,ITO Kiminari,FUJITA Haruyuki,KADOWAKI Norimitsu,ISHIKAWA Takayuki,TAKAHASHI Takayuki,Takahashi Takayuki
- Journal of clinical and experimental hematopathology 52(2), 107-111, 2012-10-01
- … These cells were positive for CD4, CD86, CD123 (bright), BDCA-2, and HLA-DR, but negative for CD1a, CD3, CD11b, CD11c, CD13, CD14, CD19, CD64, and CD68. …
- NAID 10031120434
- Blastic Plasmacytoid Dendritic Cell Neoplasm : Report of Two Cases
- TSUNODA Kanako,SATOH Takashi,AKASAKA Kiyomi,ISHIKAWA Yuichi,ISHIDA Yoji,MASUDA Tomoyuki,AKASAKA Toshihide
- Journal of clinical and experimental hematopathology 52(1), 23-29, 2012-05-01
- … Histopathology of a skin biopsy specimen and immunohistochemistry demonstrated that the tumor cells were small to medium-sized with a blastoid morphology and positive for CD4, CD56, CD123 and T-cell leukemia-1 (TCL-1). … Although immunohistochemistry of the infiltrating tumor cells demonstrated positivity for CD4, CD56, CD123 and TCL-1, the cells were large with a distinct nucleolus, and different from those of typical BPDCN. …
- NAID 10030615559
Related Pictures
★リンクテーブル★
[★]
- 英
- interleukin-3
- 同
- インターロイキン-3、インターロイキン3
- 関
- サイトカイン、インターロイキン
産生細胞
機能
- 造血初期に相乗効果的に働く
- IL-3は肥満細胞の増殖分化を誘導
- IL-3 KOマウスでは肥満細胞がない
受容体
[★]
- 同
- leucine-6, CD1A through E
種類
発現組織
- 胸腺皮質、ランゲルハンス細胞、樹状細胞、B細胞(CD1c)、腸上皮、平滑筋、血管上皮(CD1d)
分子量
機能
- MHC class I-like molecule, associated with β2-microgloulin. Has specialized role in presentation of lipid antigens